Biohaven Ltd. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$0.86. It usually reports 29–61 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 1, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 2, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–61 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-129
+25.5%
|
-0.86
+47.6%
|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-137
+30.7%
|
-0.91
+53.1%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-131
+41.1%
|
-0.88
+59.4%
|
|
Mar 2, 2026
61 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-146
+22.1%
|
-1.21
+34.5%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-173
-8.2%
|
-1.64
+3.5%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-198
+38.0%
|
-1.94
+46.7%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-222
-23.5%
|
-2.17
+1.4%
|
|
Mar 3, 2025
62 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-187
-29.1%
|
-1.85
-2.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHVN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Virgin Islands, British
- Headquarters
- New Haven, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1935979
- Former names
- Biohaven Research Ltd. (until Sep 14, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.